Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan;27(1):183-190.
doi: 10.1007/s00520-018-4312-0. Epub 2018 Jun 19.

A decrease in vitamin D levels is associated with methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia

N Oosterom  1   2   3 , N F Dirks  4 , S G Heil  5 , R de Jonge  6 , W J E Tissing  7 , R Pieters  8 , M M van den Heuvel-Eibrink  8 , A C Heijboer  4   9 , S M F Pluijm  8   10
Affiliations

A decrease in vitamin D levels is associated with methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia

N Oosterom et al. Support Care Cancer. 2019 Jan.

Abstract

Purpose: Children with acute lymphoblastic leukemia (ALL) are at increased risk of vitamin D deficiency, which might make them more susceptible to developing adverse events. Previous studies showed that low vitamin D levels were associated with an increased inflammatory mucosal state and impaired mucosal tissue barriers. We examined the prevalence of vitamin D deficiency and studied the association between vitamin D levels and methotrexate (MTX)-induced oral mucositis in pediatric ALL.

Methods: We assessed 25-hydroxyvitamin D (25(OH)D3) and 24,25-dihydroxyvitamin D (24,25(OH)2D3) levels in 99 children with ALL before the start of 4 × 5 g/m2 high-dose methotrexate (HD-MTX) (T0) and in 81/99 children after discontinuation of HD-MTX (T1). Two cutoff values for vitamin D deficiency exist: 25(OH)D3 levels < 30 and < 50 nmol/L. Oral mucositis was defined as grade ≥ 3 according to the National Cancer Institute Criteria.

Results: Vitamin D deficiency occurred in respectively 8% (< 30 nmol/L) and 33% (< 50 nmol/L) of the patients at T0, and more frequently in children > 4 years of age as compared to children between 1 and 4 years of age. A decrease in 25(OH)D3 levels during HD-MTX therapy was associated with developing severe oral mucositis (OR 1.6; 95% CI [1.1-2.4]). 25(OH)D3 and 24,25(OH)2D3 levels at T0 and the change in 24,25(OH)2D3 levels during therapy were not associated with the development of severe oral mucositis.

Conclusions: This study showed that vitamin D deficiency occurs frequently in pediatric ALL patients above the age of 4 years. A decrease in 25(OH)D3 levels during MTX therapy was observed in children with ALL that developed severe oral mucositis.

Keywords: Acute lymphoblastic leukemia; Methotrexate; Oral mucositis; Vitamin D.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Flowchart of patient inclusion. ALL, acute lymphoblastic leukemia; HD-MTX, high-dose methotrexate; DCOG, Dutch Childhood Oncology Group; SNP, single-nucleotide polymorphism; n, number of patients; * one patient had neurological damage before the start of HD-MTX treatment, one patients was transferred to another hospital, one patient had an adjusted protocol due to a SPINKS mutation, and one patient was initially treated otherwise due to another diagnosis
Fig. 2
Fig. 2
25(OH)D3 levels at T0 and T0 in relation to the development of oral mucositis. 25(OH)D3 levels at T0 and T1 in individual patients with (yes, n = 62) and without (no, n = 19) mucositis; the red lines indicate the mean 25(OH)D3 levels at T0 and T1 of all patients; the blue lines indicate the 95% confidence interval; the dotted line indicates the cutoff value of vitamin D deficiency at 25(OH)D3 levels < 50 nmol/L.
See this image and copyright information in PMC

References

    1. Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, Reaman GH, Carroll WL. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(14):1663–1669. doi: 10.1200/jco.2011.37.8018. - DOI - PMC - PubMed
    1. Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg H, de Bont E, Egeler RM, Hoogerbrugge P, Kaspers G, Van der Schoot E, De Haas V, Van Dongen J. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch Childhood Oncology Group. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(22):2591–2601. doi: 10.1200/jco.2015.64.6364. - DOI - PubMed
    1. den Hoed MA, Lopez-Lopez E, te Winkel ML, Tissing W, de Rooij JD, Gutierrez-Camino A, Garcia-Orad A, den Boer E, Pieters R, Pluijm SM, de Jonge R, van den Heuvel-Eibrink MM. Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia. Pharmacogenomics J. 2015;15(3):248–254. doi: 10.1038/tpj.2014.63. - DOI - PubMed
    1. Fink M. Vitamin D deficiency is a cofactor of chemotherapy-induced mucocutaneous toxicity and dysgeusia. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(4):e81–e82. doi: 10.1200/jco.2010.31.5317. - DOI - PubMed
    1. Pludowski P, Holick MF, Pilz S, Wagner CL, Hollis BW, Grant WB, Shoenfeld Y, Lerchbaum E, Llewellyn DJ, Kienreich K, Soni M. Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality—a review of recent evidence. Autoimmun Rev. 2013;12(10):976–989. doi: 10.1016/j.autrev.2013.02.004. - DOI - PubMed

MeSH terms